Amgen: Rectal Neoplasms trials
The registry lists 15 Rectal Neoplasms studies with Amgen as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 3Phase 2 10Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerCompletedNCT01001377Phase 3Results posted
- PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudyCompletedNCT00911170Phase 3Results posted
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsCompletedNCT00819780Phase 2Results posted
- Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer StudyCompletedNCT00630786Phase 1/2Results posted
- SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialCompletedNCT00418938Phase 2Results posted
- Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to TreatmentCompletedNCT00411450Phase 2Results posted
- Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based TherapyCompletedNCT00332163Phase 2Results posted
- PACCE: Panitumumab Advanced Colorectal Cancer Evaluation StudyCompletedNCT00115765Phase 3Results posted
- Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal CancerCompletedNCT00113763Phase 3Results posted
- Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon CancerCompletedNCT00094809Phase 2Results posted
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00752570Phase 2
- Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal CancerCompletedNCT00625651Phase 1/2
- Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal CancerCompletedNCT00113776Phase 2
- Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinomaCompletedNCT00111774Phase 2
- Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal CancerCompletedNCT00101894Phase 1